AstraZeneca PLC
AZNAstraZeneca plc (/ˌæstrəˈzɛnəkə/) (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Drugs in Pipeline
416
Phase 3 Programs
211
Upcoming Catalysts
28
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
33 upcoming, 8 past
AZD2936 Phase 2 Est. Readout
Primary completion for AZD2936 trial (NCT04995523) in Non-Small-Cell Lung Carcinoma
VISTA Phase IIb: 11.8% weight loss at 36 weeks in adults with obesity/overweight. SOLSTICE Phase IIb: 1.9% HbA1c reduction at 26 weeks in adults with type 2 diabetes
Source32 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How AZN's past catalysts played out
Baxdrostat and dapagliflozin
Heart Failure
Benralizumab Arm B
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
D961H capsule 10mg
Reflux Esophagitis
ZD9393 (Zoladex) 10.8 mg
Breast Cancer
Olaparib
Breast Cancer Metastatic
ABT-335 and rosuvastatin calcium
Hypercholesterolemia
Formoterol Turbuhaler® 4.5mg
Chronic Obstructive Pulmonary Disease
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Non-small Cell Lung Cancer
cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
AL Amyloidosis
AZD9291
Advanced Non Small Cell Lung Cancer
Baxdrostat/dapagliflozin
Chronic Kidney Disease and Hypertension
Saruparib
Prostate Cancer
Sulphonylurea
Type 2 Diabetes
Datopotamab Deruxtecan
Non-small Cell Lung Cancer
Saxagliptin, Onglyza
Type 2 Diabetes Mellitus
Theophylline
Asthma
Anastrazole (Arimidex)
Breast Cancer
Acetylsalicylic acid ASA
Acute Coronary Syndrome
Sodium Zirconium Cyclosilicate (ZS) 10g
Hyperkalemia
Oleclumab
Non-Small Cell Lung Cancer
Sodium Zirconium Cyclosilicate (ZS)
Hyperkalemia
Gefitinib
Non-Small Cell Lung Cancer
Tremelimumab
Advanced Hepatocellular Carcinoma
Aclidinium Bromide/Formoterol Fumarate
Chronic Obstructive Pulmonary Disease
Pramlintide acetate
Diabetes Mellitus, Type 1
Tozorakimab
Chronic Obstructive Pulmonary Disease (COPD)
Medi-546
Systemic Lupus Erythematosus
AZD9291 Dosing
Lung Cancer
Ciclesonide nasal spray
Hay Fever
AZD4831
Heart Failure With Preserved Ejection Fraction
Seasonal influenza virus vaccine
Asthma
Rosuvastatin 20mg
Homozygous Familial Hypercholesterolemia (HoFH)
candsartan cilexetil
Hypertension
Gemcitabine/Cisplatin
Biliary Tract Cancer
Saxagliptin 5 mg
Type 2 Diabetes Mellitus
Nexium 20mg
Erosive Esophagitis
Eplontersen
Transthyretin Amyloid Cardiomyopathy
omefas
Severe Hypertriglyceridemia
pexelizumab
Cardio-pulmonary Bypass
Benralizumab (Medi-563)
Asthma
Lithium carbonate
Acute Bipolar Depression
Metformin XR
Type 2 Diabetes
Dato-DXd
Breast Cancer
SSRI/Clomipramine
Obsessive Compulsive Disorder
MEDI4736 + Tremelimumab
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Escitalopram oxylate
Generalized Anxiety Disorder
Mepolizumab
Eosinophilic Granulomatous Vasculitis
Dapagliflozin 10 mg
Diabetes Mellitus, Non-Insulin-Dependent
Symbicort
COPD Patients
Benralizumab
Asthma
exenatide
Type 2 Diabetes Mellitus
Aclidinium Bromide / Formoterol Fumarate
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium bromide
Chronic Obstructive Pulmonary Disease (COPD)
MEDI8897
Respiratory Syncytial Virus Infections
Saxagliptin, 5 mg + insulin
Type 2 Diabetes
Exenatide (AC2993)
Diabetes Mellitus, Type 2
HFO-1234ze(E)
Mucociliary Clearance
Osimertinib
Lung Cancer
Tiotropium
Chronic Obstructive Pulmonary Disease (COPD)
Terbutaline sulphate
Asthma
ALXN2060
Symptomatic Transthyretin Amyloid Cardiomyopathy
Selumetinib
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Metformin (blinded)
Type 2 Diabetes
Ciclesonide
Perennial Allergic Rhinitis
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
Chronic Obstructive Pulmonary Disease
Experimental: Tezepelumab
Chronic Rhinosinusitis With Nasal Polyps
Baxdrostat
Resistant Hypertension
TC-5214
Major Depressive Disorder
Tezepelumab
Moderate to Severe Asthma
AZD9833
ER-Positive HER2-Negative Breast Cancer
Benralizumab Arm A
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
formoterol
Asthma
10mg Rosuvastatin
Renal Failure
Saxagliptin
Type 2 Diabetes
Gefitinib (Iressa)
Cancer
MEDI4736
Squamous Cell Carcinoma of the Head and Neck
Candesartan cilexetil
Hypertension
BCG
Non-Muscle- Invasive Bladder Cancer
Durvalumab (MEDI4736)
Non-muscle-invasive Bladder Cancer
exenatide, long acting release
Type 2 Diabetes Mellitus
Rosuvastatin (Crestor)
Hypercholesterolemia
BGF MDI 320/28.8/9.6 μg
Asthma
Tezepelumab (APFS)
Asthma
BGF MDI HFO 320/14.4/9.6 μg
Chronic Obstructive Pulmonary Disease (COPD)
Datopotamab deruxtecan (Dato-DXd)
Non-small Cell Lung Cancer (NSCLC)
Saxagliptin 5mg
Type 2 Diabetes Mellitus
exenatide once weekly
Type 2 Diabetes Mellitus
Gefitinib, raltitrexed
Colorectal Cancer
Zibotentan/Dapagliflozin
Chronic Kidney Disease With High Proteinuria
ABT-335 plus rosuvastatin
Dyslipidemia
Acetylsalicylic acid (ASA)
Acute Ischaemic Stroke
ATACAND
Hypertension
AC2993
Diabetes Mellitus, Type 2
Symbicort Turbuhaler
Bronchial Asthma
rosiglitazone
Diabetes Mellitus, Type 2
Durvalumab plus chemotherapy
Small Cell Lung Carcinoma Extensive Disease
AZD5156 (Parent study Sentinel Safety Cohort)
COVID-19, SARS-CoV-2
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level
Hyperkalaemia
5-fluorouracil
Colorectal Cancer
Saxagliptin 2.5 mg
Type 2 Diabetes Mellitus, CKD and Albuminuria
Saxagliptin + Metformin
Diabetes Mellitus, Type 2
Nirsevimab
Respiratory Syncytial Virus Infections
D9421-C capsule 3 mg
Crohn's Disease
Pulmicort Turbuhaler
Asthma
Camizestrant
Advanced Breast Cancer
Cimetidine
Stress Ulcer Prophylaxis
Ticagrelor 60 mg
Diabetes Mellitus, Type 2
Gemcitabine monotherapy
Biliary Tract Cancer
FLOT chemotherapy
Gastrointestinal Neoplasms
Rilvegostomig
Hepatocellular Carcinoma
Daptomycin
Skin Diseases
5-fluorouracil ( in FOLFOX)
Colorectal Cancer
Epanova
Hypertriglyceridemia
MEDI4736 (durvalumab)
Non - Small Cell Lung Cancer NSCLC
Intralipid
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
exenatide twice daily (BID)
Type 2 Diabetes Mellitus
BGF MDI HFO 320/14.4/9.6μg
COPD (Chronic Obstructive Pulmonary Disease)
Thiazolidinedione (Pioglitazone)
Type 2 Diabetes
Roxadustat
Anemia
Cisplatin + Gemcitabine
Unresectable Locally Advanced Urothelial Cancer
ABT-143
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
ZD4054
Prostate Cancer
Capivasertib
Triple Negative Breast Neoplasms
corn oil control
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Dapagliflozin 5 mg
Type 1 Diabetes Mellitus
Conventional Asthma Therapy
Asthma
Pemetrexed/Carboplatin
Non-Small Cell Lung Cancer
pravastatin
Hyperlipoproteinemia Type III
candesartan cilexetil (Atacand)
Hypertension
AZD1222
COVID-19
Durvalumab + SoC chemotherapy
Carcinoma, Non-Small-Cell Lung
ZD1839 (Gefitinib)
Carcinoma
Amitriptyline
Major Depressive Disorder
faslodex 500mg
Hormone Receptor Positive Breast Cancer
Single agent chemotherapy
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Carboplatin+Paclitaxel
Advanced Ovarian Cancer
Olaparib 300mg tablets
Relapsed Ovarian Cancer
Active Comparator: Olaparib tablets
Epithelial Ovarian Cancer
NKTR-118
Opioid-Induced Constipation (OIC)
Osimertinib 80mg/40mg
Non Small Cell Lung Cancer (Stage III)
Zirconium Cyclosilicate
Hyperkalemia
Cediranib
Metastatic Colorectal Cancer
Metformin IR
Type 2 Diabetes
Lomustine Chemotherapy
Recurrent Glioblastoma
AZD2816
COVID-19
Rosuvastatin Dose 1
Dyslipidaemia
Roflumilast
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium Bromide 200 µg
Chronic Obstructive Pulmonary Disease
Symbicort pMDI
Asthma
Acalabrutinib
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Seroquel SR
Schizophrenia
Anifrolumab
Lupus Nephritis
Savolitinib
Carcinoma
Aclidinium bromide 200 μg bid
Chronic Obstructive Pulmonary Disease (COPD)
Exantide with Dapagliflozin
Diabetes Mellitus
Epoetin alfa
Anemia
Sodium Zirconium Cyclosilicate
Hyperkalemia
AZD5335
Epithelial Ovarian Cancer
divalproex
Bipolar I Disorder
Rosuvastatin calcium
Hypercholesteremia
tralokinumab
Ulcerative Colitis
Zolmitriptan
Migraine
MEDI3250
Healthy Japanese Children Age 7 Years Through 18 Years
AZD0780
Heterozygous Familial Hypercholesterolaemia
exenatide/insulin glargine
Type 2 Diabetes Mellitus
Candesartan
Congestive Heart Failure
lithium
Bipolar I Disorder
Exenatide once weekly suspension
Diabetes Mellitus, Type 2
budesonode bid + terbutaline 'as needed'
Asthma
insulin lispro
Type 2 Diabetes Mellitus
Metformin immediate release (IR)
Type 2 Diabetes
Saxagliptin plus metformin IR
Type 2 Diabetes Mellitus
Symbicort TBH - Turbuhaler
Asthma
Olive oil, 4g
Hypertriglyceridemia
glipizide
Type 2 Diabetes
Terbutaline Turbuhaler®
Asthma
Linaclotide
Irritable Bowel Syndrome With Constipation (IBS-C)
(Osimertinib cohort, single-arm, open-label separate cohort)
Carcinoma, Non-Small-Cell Lung
BFF MDI 320/9.6 μg
Asthma
NXY-059
Intracerebral Hemorrhage
CRESTOR
Heart Failure
Pertuzumab
Breast Neoplasms
Seroquel Sustained Release (SR)
Schizophrenic Disorder
cisplatin + fluorouracil
Esophageal Squamous Cell Carcinoma
Ravulizumab
Thrombotic Microangiopathy
CAEL-101
AL Amyloidosis
AZD7442
COVID-19
Sebelipase alfa (SBC-102)
Lysosomal Acid Lipase Deficiency
Eculizumab
Atypical Hemolytic Uremic Syndrome
Surovatamig
B-cell Non-Hodgkin Lymphoma
Ticagrelor
Acute Coronary Syndrome
Volrustomig
Non-small Cell Lung Cancer
Eculizumab (Soliris®)
Shiga-like Toxin-producing Escherichia Coli
Andexanet
Bleeding
Epanova® (omega-3 carboxylic acids)
Diabetes Mellitus, Type 2
Casdatifan
Advanced Clear Cell Renal Cell Carcinoma
ALXN1850
Hypophosphatasia
ALXN2220
Transthyretin Amyloid Cardiomyopathy
sebelipase alfa
Cholesterol Ester Storage Disease (CESD)
C5 Inhibitor
Paroxysmal Nocturnal Hemoglobinuria
Danicopan
C3 Glomerulonephritis
asfotase alfa
Hypophosphatasia
pexelizumab in conjunction with CABG
Coronary Artery Disease
Tozorakimab Dose Regimen 1
Chronic Obstructive Pulmonary Disease
Sonesitatug vedotin
Gastric Cancer
AZD1152
Acute Myeloid Leukemia
Chemotherapy
Anticancer Treatment
Saruparib (AZD5305)
Ovarian Cancer
exenatide twice daily
Type 2 Diabetes Mellitus
Ciclesonide nasal
Rhinitis, Allergic, Perennial
fostamatinib
Rheumatoid Arthritis
AC2993 (exenatide)
Diabetes Mellitus
AZD6234
Obesity/Overweight
MEDI6570
Coronary Heart Disease (CHD)
Tremelimumab monotherapy
Urothelial Bladder Cancer
B - Exenatide 10 mcg twice daily
Diabetes Mellitus, Type 2
ZD1839
Mesothelioma
Exenatide LAR
Type 2 Diabetes Mellitus
plevitrexed
Fallopian Tube Cancer
Ticagrelor Dose 1a + Dose 2a
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
AZD1981
Asthma
AZD0865
GERD Without Erosive Esophagitis
SBC-103
Mucopolysaccharidosis IIIB
Atuliflapon
Asthma
AZD3470
Lymphoma
AZD9773
Severe Sepsis
AZD7789
Carcinoma, Non-Small-Cell Lung
AZD1940
Pain
Aclidinium 400 μg / Formoterol 12 μg
Chronic Obstructive Pulmonary Disease
AZD9793 Intravenous (IV) monotherapy
Hepatocellular Carcinoma
Anastrazole
Breast Cancer
Cotadutide
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Sovaprevir
Hepatitis C, Chronic
AZD2927
Arrhythmia
cediranib and olaparib
Recurrent Platinum Resistant Ovarian Cancer
MEDI3506
Atopic Dermatitis
AZD0022
Advanced Solid Tumours
lesogaberan (AZD3355)
Gastroesophageal Reflux Disease
pramlintide acetate 360 mcg
Overweight
AZD2171
Metastatic Colorectal Cancer
AZD5363 when combined with weekly paclitaxel.
Advanced or Metastatic Breast Cancer
ACH-0144471
Paroxysmal Nocturnal Hemoglobinuria
AZD7648
Advanced Malignancies
ACH-0141625 (Sovaprevir)
Hepatitis C
Tarperprumig
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
CP-675,206
Malignant Melanoma
AZD1305
Atrial Fibrillation
GC012F (AZD0120)
Relapsed/ Refractory Multiple Myeloma
AZD8848
Allergic Asthma
Tiotropium 18 μg once-daily
Chronic Obstructive Pulmonary Disease (COPD)
AZD9056
Rheumatoid Arthritis
Casodex
Gynaecomastia
Lenvatinib
Hepatocellular Carcinoma
AZD7594 DPI 55μg/50μg.
Asthma
AZD5423
Chronic Obstructive Pulmonary Disease (COPD)
Iressa
Locally Advanced Prostate Cancer
AZD9164
Chronic Obstructive Pulmonary Disease
Bis-Choline Tetrathiomolybdate
Wilson Disease
Ticagrelor Tablets
Coronary Artery Disease
Formoterol Fumarate in the Pressair DPI, Low Dose
Asthma
Bertilimumab
Pemphigoid, Bullous
Sebelipase alfa 0.35 mg/kg
Cholesterol Ester Storage Disease(CESD)
KU-0059436 (AZD2281)(PARP inhibitor)
Ovarian Neoplasm
AZD2936
Non-Small-Cell Lung Carcinoma
AZD5492
B-cell Malignancies
Part A:AZD8233
Dyslipidemia
AZD2281
Ovarian Neoplasms
80/2.25 μg Symbicort pMDI
Asthma
AZD5851
Hepatocellular Carcinoma
sibutramine
Overweight
Sodium Zirconium Cyclosilicate(ZS)
Hyperkalemia
Anastrozole and goserelin
Breast Cancer
AZD8931
Neoplasms
Gefitinib, Cisplatin and Radiotherapy
Cancer of Head and Neck
AZD4017
Raised Intraocular Pressure
AZD2423
Chronic Obstructive Pulmonary Disease
Ceralasertib
Advanced Solid Tumours
AZD4818
Chronic Obstructive Pulmonary Disease (COPD)
Interferon beta-1a Nebuliser solution 48 μg/mL
Asthma
AC2993 2.5 mcg
Diabetes Mellitus, Non-Insulin-Dependent
AZD3480
ADHD
Biological: AZD3152
COVID-19, SARS-CoV-2
VKA INR 2-3
Persistent or Permanent Nonvalvular Atrial Fibrillation
AZD4360
Gastric Cancer
FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Metastatic Colorectal Cancer
Selumetinib 75 mg
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AZD4117
Influenza A
Aclidinium bromide 100 μg bid
Chronic Obstructive Pulmonary Disease (COPD)
AC2592
Congestive Heart Failure
AZD7325
Anxiety Disorders
AZD5462
Chronic Heart Failure
CIN-107
Uncontrolled Hypertension
AZD8630
Asthma
AZD2389
Liver Fibrosis
ER tablet 25 mg AZD3241
Parkinson's Disease
Aclidinium/formoterol 400/12μg
Chronic Obstructive Pulmonary Disease (COPD)
Gefitinib, radiotherapy
Non-Metastatic Prostate Cancer
Cotadutide 100 micrograms
Type 2 Diabetes Mellitus
MEDI4736 monotherapy
Metastatic Pancreatic Ductal Adenocarcinoma
AZD9773 (CytoFab)
Severe Sepsis
AZD8421
ER+ HER2- Advanced Breast Cancer
Durvalumab and Tremelimumab
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Cediranib 30 - 90 mg
Cancer
ACH-126,443
Hepatitis B, Chronic
ALXN2350
BAG3 Mutation Associated Dilated Cardiomyopathy
Aclidinium 200 μg / formoterol 12 μg
Chronic Obstructive Pulmonary Disease
ALXN2420
Acromegaly
ALXN1210
PNH
AZD3427
Pulmonary Hypertension (World Health Organization Group 2)
Mitiperstat (AZD4831)
Chronic Obstructive Pulmonary Disease (COPD)
AZD7798
Crohn's Disease
AZD6765
Treatment Resistant Major Depressive Disorder
Pramlintide and Metreleptin
Obesity
Omega-3 carboxylic acid
Non-alcoholic Fatty Liver Disease (NAFLD
terbutaline
Exercise Induced Asthma
Gefitinib and capecitabine
Colorectal Cancer
BMS-512148
Diabetes Mellitus, Type 2
Monalizumab
Non-small Cell Lung Cancer
AZD1656
Type 2 Diabetes Mellitus
Anastrozole (ARIMIDEX™)
Gynecomastia
AB248
Advanced or Metastatic Non-small Cell Lung Cancer
AZD2066
Reflux Episodes
Fluorouracil (5-FU)
Gastric Cancer
Goserelin acetate
Advanced Breast Cancer
SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
AL Amyloidosis
AZD3241
Multiple System Atrophy, MSA
AS MDI 90 μg
Asthma
AZD2693
Nonalcoholic Steatohepatitis
AZD8233
Hyperlipidaemia
AZD3241 300 mg BID
Parkinson's Disease
AZD6750
Melanoma
D9421-C, 9mg
Crohn's Disease
AS MDI
Asthma
Adavosertib
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
AZP-3601
Chronic Hypoparathyroidism
AZD4901 (oral)
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
AZD 8529
Schizophrenia
MEDI7352
Painful Osteoarthritis of the Knee
AZD9567
Diabetes Mellitus, Type 2
AZD9668
Chronic Obstructive Pulmonary Disease
AZD6621
Prostate Cancer
800 μg AZD7594 once daily
Asthma
AZD8601
Heart Failure
5-flourouracil
Squamous Cell Cancer
MEDI-545
Systemic Lupus Erythematosus
AZD4635
Prostate Cancer
AZD6094
Papillary Renal Cell Cancer
AZD0120
Lupus Erythematosus, Systemic
AZD3199
COPD
AC2307
Obesity
AZD5213
Mild Cognitive Impairment
5-Fluorouracil (5-FU)
Gastroesophageal Adenocarcinoma
Administration of ceralasertib
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Danvatirsen
Non-Small Cell Lung Cancer
AZD5718
Coronary Artery Disease
MEDI2070
Crohn's Disease
Verinurad 9 mg+Febuxostat 80 mg
Hyperuricemia
AZD3355
GERD
ICI35,868 (propofol)
Gastrointestinal Endoscopy
exenatide (LY2148568)
Type 2 Diabetes Mellitus
AZD4604
Asthma
0.5% Roflumilast Cream
Atopic Dermatitis
AZD6244
Non Small Cell Lung Cancer
Verinurad
Chronic Kidney Disease
Ciclesonide/Formoterol Combination
Asthma
Olaparib Continuous (28-Day cycle) 300 mg BD.
Metastatic Triple Negative Breast Cancer
metreleptin
Overweight
RDEA3170
Gout and Hyperuricemia
AZD9550
Overweight and Obesity
AZD8871
Chronic Obstructive Pulmonary Disease
AZD2115
COPD
Epanova (4 g) and Lovaza (4 g)
Severe Hypertriglyceridemia
AZD7009, no generic name available
Atrial Fibrillation
600 mg AZD7442 IV
Coronavirus Disease 2019 (COVID-19)
AZD5069 50mg
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
AZD2327
Anxious Major Depressive Disorder
Cerdulatinib
Follicular Lymphoma (FL/Indolent NHL)
AZD9977
Heart Failure
ZD4054 10 mg
Prostatic Neoplasms
AZD0837
Nonvalvular Atrial Fibrillation
ALXN1920
Primary Membranous Nephropathy
AZD0901
Gastric Cancer
CP-675,206 and leuprolide acetate and bicalutamide
Prostatic Neoplasms
AZD1446
Adult ADHD
AZD0486
Chronic Lymphocytic Leukaemia
AZD9150
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
AZD0171
Locally Advanced or Metastatic Solid Tumours
AZD8205
Breast Cancer
Leucovorin LV
Endometrial Cancer
gefitinib and fulvestrant
Breast Cancer
Osimertinib + Savolitinib
Non-Small Cell Lung Cancer
Salmeterol
Chronic Obstructive Pulmonary Disease
Lamivudine
HIV Infections
AZD4512
B-cell Non-Hodgkin Lymphoma
AZD1163
Rheumatoid Arthritis
Neoadjuvant Olaparib monotherapy group
Breast Cancer
AZD0530
Breast Cancer
AZD5305
Ovarian Cancer
AZD7760
Staphylococcus Aureus
AZD4573
Advanced Haematological Malignancies
AZD2624
Schizophrenia
Elvucitabine
Human Immunodeficiency Virus (HIV)-1 Infection
AZD9829
Hematological Malignancies
AZD8871 100 µg
Chronic Obstructive Pulmonary Disease COPD
MEDI0382 low dose
Diabetes Mellitus, Type 2
ALXN2030
Antibody-Mediated Rejection
AZD0754
Metastatic Prostate Cancer
ALXN1840
Wilson Disease
AZD5004
Diabetes Mellitus, Type 2
LAS100977 0.313 μg
Asthma
AZD5069
Asthma
AZD8683, 50 mcg
Chronic Obstructive Pulmonary Disease (COPD)
AZD9574
Advanced Solid Malignancies
Formoterol fumarate (6 μg)
Chronic Obstructive Pulmonary Disease - COPD
Osimertinib 80 mg/40 mg
Stage II-IIIB Non-small Cell Lung Carcinoma
ZD1839 (IRESSA™)
Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Baxdrostat and dapagliflozin | Phase 3 | Heart Failure | - | - |
Benralizumab Arm B | Phase 3 | Moderate to Very Severe Chronic Obstructive Pulmonary Disease | - | - |
D961H capsule 10mg | Phase 3 | Reflux Esophagitis | - | - |
ZD9393 (Zoladex) 10.8 mg | Phase 3 | Breast Cancer | - | - |
Olaparib | Phase 3 | Breast Cancer Metastatic | - | - |
ABT-335 and rosuvastatin calcium | Phase 3 | Hypercholesterolemia | - | - |
Formoterol Turbuhaler® 4.5mg | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen | Phase 3 | AL Amyloidosis | - | - |
AZD9291 | Phase 3 | Advanced Non Small Cell Lung Cancer | - | - |
Baxdrostat/dapagliflozin | Phase 3 | Chronic Kidney Disease and Hypertension | - | - |
Saruparib | Phase 3 | Prostate Cancer | - | - |
Sulphonylurea | Phase 3 | Type 2 Diabetes | - | - |
Datopotamab Deruxtecan | Phase 3 | Non-small Cell Lung Cancer | - | - |
Saxagliptin, Onglyza | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Theophylline | Phase 3 | Asthma | - | - |
Anastrazole (Arimidex) | Phase 3 | Breast Cancer | - | - |
Acetylsalicylic acid ASA | Phase 3 | Acute Coronary Syndrome | - | - |
Sodium Zirconium Cyclosilicate (ZS) 10g | Phase 3 | Hyperkalemia | - | - |
Oleclumab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Sodium Zirconium Cyclosilicate (ZS) | Phase 3 | Hyperkalemia | - | - |
Gefitinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tremelimumab | Phase 3 | Advanced Hepatocellular Carcinoma | - | - |
Aclidinium Bromide/Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Pramlintide acetate | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Tozorakimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Medi-546 | Phase 3 | Systemic Lupus Erythematosus | - | - |
AZD9291 Dosing | Phase 3 | Lung Cancer | - | - |
Ciclesonide nasal spray | Phase 3 | Hay Fever | - | - |
AZD4831 | Phase 3 | Heart Failure With Preserved Ejection Fraction | - | - |
Seasonal influenza virus vaccine | Phase 3 | Asthma | - | - |
Rosuvastatin 20mg | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | - | - |
candsartan cilexetil | Phase 3 | Hypertension | - | - |
Gemcitabine/Cisplatin | Phase 3 | Biliary Tract Cancer | - | - |
Saxagliptin 5 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Nexium 20mg | Phase 3 | Erosive Esophagitis | - | - |
Eplontersen | Phase 3 | Transthyretin Amyloid Cardiomyopathy | - | - |
omefas | Phase 3 | Severe Hypertriglyceridemia | - | - |
pexelizumab | Phase 3 | Cardio-pulmonary Bypass | - | - |
Benralizumab (Medi-563) | Phase 3 | Asthma | - | - |
Lithium carbonate | Phase 3 | Acute Bipolar Depression | - | - |
Metformin XR | Phase 3 | Type 2 Diabetes | - | - |
Dato-DXd | Phase 3 | Breast Cancer | - | - |
SSRI/Clomipramine | Phase 3 | Obsessive Compulsive Disorder | - | - |
MEDI4736 + Tremelimumab | Phase 3 | Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | - | - |
Escitalopram oxylate | Phase 3 | Generalized Anxiety Disorder | - | - |
Mepolizumab | Phase 3 | Eosinophilic Granulomatous Vasculitis | - | - |
Dapagliflozin 10 mg | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Symbicort | Phase 3 | COPD Patients | - | - |
Benralizumab | Phase 3 | Asthma | - | - |
exenatide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Aclidinium Bromide / Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Aclidinium bromide | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
MEDI8897 | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Saxagliptin, 5 mg + insulin | Phase 3 | Type 2 Diabetes | - | - |
Exenatide (AC2993) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
HFO-1234ze(E) | Phase 3 | Mucociliary Clearance | - | - |
Osimertinib | Phase 3 | Lung Cancer | - | - |
Tiotropium | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Terbutaline sulphate | Phase 3 | Asthma | - | - |
ALXN2060 | Phase 3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | - | - |
Selumetinib | Phase 3 | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | - | - |
Metformin (blinded) | Phase 3 | Type 2 Diabetes | - | - |
Ciclesonide | Phase 3 | Perennial Allergic Rhinitis | - | - |
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Experimental: Tezepelumab | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
Baxdrostat | Phase 3 | Resistant Hypertension | - | - |
TC-5214 | Phase 3 | Major Depressive Disorder | - | - |
Tezepelumab | Phase 3 | Moderate to Severe Asthma | - | - |
AZD9833 | Phase 3 | ER-Positive HER2-Negative Breast Cancer | - | - |
Benralizumab Arm A | Phase 3 | Moderate to Very Severe Chronic Obstructive Pulmonary Disease | - | - |
formoterol | Phase 3 | Asthma | - | - |
10mg Rosuvastatin | Phase 3 | Renal Failure | - | - |
Saxagliptin | Phase 3 | Type 2 Diabetes | - | - |
Gefitinib (Iressa) | Phase 3 | Cancer | - | - |
MEDI4736 | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Candesartan cilexetil | Phase 3 | Hypertension | - | - |
BCG | Phase 3 | Non-Muscle- Invasive Bladder Cancer | - | - |
Durvalumab (MEDI4736) | Phase 3 | Non-muscle-invasive Bladder Cancer | - | - |
exenatide, long acting release | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Rosuvastatin (Crestor) | Phase 3 | Hypercholesterolemia | - | - |
BGF MDI 320/28.8/9.6 μg | Phase 3 | Asthma | - | - |
Tezepelumab (APFS) | Phase 3 | Asthma | - | - |
BGF MDI HFO 320/14.4/9.6 μg | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Datopotamab deruxtecan (Dato-DXd) | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Saxagliptin 5mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
exenatide once weekly | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Gefitinib, raltitrexed | Phase 3 | Colorectal Cancer | - | - |
Zibotentan/Dapagliflozin | Phase 3 | Chronic Kidney Disease With High Proteinuria | - | - |
ABT-335 plus rosuvastatin | Phase 3 | Dyslipidemia | - | - |
Acetylsalicylic acid (ASA) | Phase 3 | Acute Ischaemic Stroke | - | - |
ATACAND | Phase 3 | Hypertension | - | - |
AC2993 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Symbicort Turbuhaler | Phase 3 | Bronchial Asthma | - | - |
rosiglitazone | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Durvalumab plus chemotherapy | Phase 3 | Small Cell Lung Carcinoma Extensive Disease | - | - |
AZD5156 (Parent study Sentinel Safety Cohort) | Phase 3 | COVID-19, SARS-CoV-2 | - | - |
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level | Phase 3 | Hyperkalaemia | - | - |
5-fluorouracil | Phase 3 | Colorectal Cancer | - | - |
Saxagliptin 2.5 mg | Phase 3 | Type 2 Diabetes Mellitus, CKD and Albuminuria | - | - |
Saxagliptin + Metformin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Nirsevimab | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
D9421-C capsule 3 mg | Phase 3 | Crohn's Disease | - | - |
Pulmicort Turbuhaler | Phase 3 | Asthma | - | - |
Camizestrant | Phase 3 | Advanced Breast Cancer | - | - |
Cimetidine | Phase 3 | Stress Ulcer Prophylaxis | - | - |
Ticagrelor 60 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Gemcitabine monotherapy | Phase 3 | Biliary Tract Cancer | - | - |
FLOT chemotherapy | Phase 3 | Gastrointestinal Neoplasms | - | - |
Rilvegostomig | Phase 3 | Hepatocellular Carcinoma | - | - |
Daptomycin | Phase 3 | Skin Diseases | - | - |
5-fluorouracil ( in FOLFOX) | Phase 3 | Colorectal Cancer | - | - |
Epanova | Phase 3 | Hypertriglyceridemia | - | - |
MEDI4736 (durvalumab) | Phase 3 | Non - Small Cell Lung Cancer NSCLC | - | - |
Intralipid | Phase 3 | Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy | - | - |
exenatide twice daily (BID) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
BGF MDI HFO 320/14.4/9.6μg | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | - | - |
Thiazolidinedione (Pioglitazone) | Phase 3 | Type 2 Diabetes | - | - |
Roxadustat | Phase 3 | Anemia | - | - |
Cisplatin + Gemcitabine | Phase 3 | Unresectable Locally Advanced Urothelial Cancer | - | - |
ABT-143 | Phase 3 | Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia | - | - |
ZD4054 | Phase 3 | Prostate Cancer | - | - |
Capivasertib | Phase 3 | Triple Negative Breast Neoplasms | - | - |
corn oil control | Phase 3 | Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD) | - | - |
Dapagliflozin 5 mg | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Conventional Asthma Therapy | Phase 3 | Asthma | - | - |
Pemetrexed/Carboplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
pravastatin | Phase 3 | Hyperlipoproteinemia Type III | - | - |
candesartan cilexetil (Atacand) | Phase 3 | Hypertension | - | - |
AZD1222 | Phase 3 | COVID-19 | - | - |
Durvalumab + SoC chemotherapy | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
ZD1839 (Gefitinib) | Phase 3 | Carcinoma | - | - |
Amitriptyline | Phase 3 | Major Depressive Disorder | - | - |
faslodex 500mg | Phase 3 | Hormone Receptor Positive Breast Cancer | - | - |
Single agent chemotherapy | Phase 3 | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | - | - |
Carboplatin+Paclitaxel | Phase 3 | Advanced Ovarian Cancer | - | - |
Olaparib 300mg tablets | Phase 3 | Relapsed Ovarian Cancer | - | - |
Active Comparator: Olaparib tablets | Phase 3 | Epithelial Ovarian Cancer | - | - |
NKTR-118 | Phase 3 | Opioid-Induced Constipation (OIC) | - | - |
Osimertinib 80mg/40mg | Phase 3 | Non Small Cell Lung Cancer (Stage III) | - | - |
Zirconium Cyclosilicate | Phase 3 | Hyperkalemia | - | - |
Cediranib | Phase 3 | Metastatic Colorectal Cancer | - | - |
Metformin IR | Phase 3 | Type 2 Diabetes | - | - |
Lomustine Chemotherapy | Phase 3 | Recurrent Glioblastoma | - | - |
AZD2816 | Phase 3 | COVID-19 | - | - |
Rosuvastatin Dose 1 | Phase 3 | Dyslipidaemia | - | - |
Roflumilast | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Aclidinium Bromide 200 µg | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Symbicort pMDI | Phase 3 | Asthma | - | - |
Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | - | - |
Seroquel SR | Phase 3 | Schizophrenia | - | - |
Anifrolumab | Phase 3 | Lupus Nephritis | - | - |
Savolitinib | Phase 3 | Carcinoma | - | - |
Aclidinium bromide 200 μg bid | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Exantide with Dapagliflozin | Phase 3 | Diabetes Mellitus | - | - |
Epoetin alfa | Phase 3 | Anemia | - | - |
Sodium Zirconium Cyclosilicate | Phase 3 | Hyperkalemia | - | - |
AZD5335 | Phase 3 | Epithelial Ovarian Cancer | - | - |
divalproex | Phase 3 | Bipolar I Disorder | - | - |
Rosuvastatin calcium | Phase 3 | Hypercholesteremia | - | - |
tralokinumab | Phase 3 | Ulcerative Colitis | - | - |
Zolmitriptan | Phase 3 | Migraine | - | - |
MEDI3250 | Phase 3 | Healthy Japanese Children Age 7 Years Through 18 Years | - | - |
AZD0780 | Phase 3 | Heterozygous Familial Hypercholesterolaemia | - | - |
exenatide/insulin glargine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Candesartan | Phase 3 | Congestive Heart Failure | - | - |
lithium | Phase 3 | Bipolar I Disorder | - | - |
Exenatide once weekly suspension | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
budesonode bid + terbutaline 'as needed' | Phase 3 | Asthma | - | - |
insulin lispro | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Metformin immediate release (IR) | Phase 3 | Type 2 Diabetes | - | - |
Saxagliptin plus metformin IR | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Symbicort TBH - Turbuhaler | Phase 3 | Asthma | - | - |
Olive oil, 4g | Phase 3 | Hypertriglyceridemia | - | - |
glipizide | Phase 3 | Type 2 Diabetes | - | - |
Terbutaline Turbuhaler® | Phase 3 | Asthma | - | - |
Linaclotide | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | - | - |
(Osimertinib cohort, single-arm, open-label separate cohort) | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
BFF MDI 320/9.6 μg | Phase 3 | Asthma | - | - |
NXY-059 | Phase 3 | Intracerebral Hemorrhage | - | - |
CRESTOR | Phase 3 | Heart Failure | - | - |
Pertuzumab | Phase 3 | Breast Neoplasms | - | - |
Seroquel Sustained Release (SR) | Phase 3 | Schizophrenic Disorder | - | - |
cisplatin + fluorouracil | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
Ravulizumab | Phase 3 | Thrombotic Microangiopathy | - | - |
CAEL-101 | Phase 3 | AL Amyloidosis | - | - |
AZD7442 | Phase 3 | COVID-19 | - | - |
Sebelipase alfa (SBC-102) | Phase 3 | Lysosomal Acid Lipase Deficiency | - | - |
Eculizumab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - | - |
Surovatamig | Phase 3 | B-cell Non-Hodgkin Lymphoma | - | - |
Ticagrelor | Phase 3 | Acute Coronary Syndrome | - | - |
Volrustomig | Phase 3 | Non-small Cell Lung Cancer | - | - |
Eculizumab (Soliris®) | Phase 3 | Shiga-like Toxin-producing Escherichia Coli | - | - |
Andexanet | Phase 3 | Bleeding | - | - |
Epanova® (omega-3 carboxylic acids) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Casdatifan | Phase 3 | Advanced Clear Cell Renal Cell Carcinoma | - | - |
ALXN1850 | Phase 3 | Hypophosphatasia | - | - |
ALXN2220 | Phase 3 | Transthyretin Amyloid Cardiomyopathy | - | - |
sebelipase alfa | Phase 3 | Cholesterol Ester Storage Disease (CESD) | - | - |
C5 Inhibitor | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Danicopan | Phase 3 | C3 Glomerulonephritis | - | - |
asfotase alfa | Phase 3 | Hypophosphatasia | - | - |
pexelizumab in conjunction with CABG | Phase 3 | Coronary Artery Disease | - | - |
Tozorakimab Dose Regimen 1 | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Sonesitatug vedotin | Phase 3 | Gastric Cancer | - | - |
AZD1152 | Phase 3 | Acute Myeloid Leukemia | - | - |
Chemotherapy | Phase 3 | Anticancer Treatment | - | - |
Saruparib (AZD5305) | Phase 3 | Ovarian Cancer | - | - |
exenatide twice daily | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ciclesonide nasal | Phase 3 | Rhinitis, Allergic, Perennial | - | - |
fostamatinib | Phase 3 | Rheumatoid Arthritis | - | - |
AC2993 (exenatide) | Phase 2 | Diabetes Mellitus | - | - |
AZD6234 | Phase 2 | Obesity/Overweight | - | - |
MEDI6570 | Phase 2 | Coronary Heart Disease (CHD) | - | - |
Tremelimumab monotherapy | Phase 2 | Urothelial Bladder Cancer | - | - |
B - Exenatide 10 mcg twice daily | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ZD1839 | Phase 2 | Mesothelioma | - | - |
Exenatide LAR | Phase 2 | Type 2 Diabetes Mellitus | - | - |
plevitrexed | Phase 2 | Fallopian Tube Cancer | - | - |
Ticagrelor Dose 1a + Dose 2a | Phase 2 | Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease | - | - |
AZD1981 | Phase 2 | Asthma | - | - |
AZD0865 | Phase 2 | GERD Without Erosive Esophagitis | - | - |
SBC-103 | Phase 2 | Mucopolysaccharidosis IIIB | - | - |
Atuliflapon | Phase 2 | Asthma | - | - |
AZD3470 | Phase 2 | Lymphoma | - | - |
AZD9773 | Phase 2 | Severe Sepsis | - | - |
AZD7789 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
AZD1940 | Phase 2 | Pain | - | - |
Aclidinium 400 μg / Formoterol 12 μg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD9793 Intravenous (IV) monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |
Anastrazole | Phase 2 | Breast Cancer | - | - |
Cotadutide | Phase 2 | Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | - | - |
Sovaprevir | Phase 2 | Hepatitis C, Chronic | - | - |
AZD2927 | Phase 2 | Arrhythmia | - | - |
cediranib and olaparib | Phase 2 | Recurrent Platinum Resistant Ovarian Cancer | - | - |
MEDI3506 | Phase 2 | Atopic Dermatitis | - | - |
AZD0022 | Phase 2 | Advanced Solid Tumours | - | - |
lesogaberan (AZD3355) | Phase 2 | Gastroesophageal Reflux Disease | - | - |
pramlintide acetate 360 mcg | Phase 2 | Overweight | - | - |
AZD2171 | Phase 2 | Metastatic Colorectal Cancer | - | - |
AZD5363 when combined with weekly paclitaxel. | Phase 2 | Advanced or Metastatic Breast Cancer | - | - |
ACH-0144471 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
AZD7648 | Phase 2 | Advanced Malignancies | - | - |
ACH-0141625 (Sovaprevir) | Phase 2 | Hepatitis C | - | - |
Tarperprumig | Phase 2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | - | - |
CP-675,206 | Phase 2 | Malignant Melanoma | - | - |
AZD1305 | Phase 2 | Atrial Fibrillation | - | - |
GC012F (AZD0120) | Phase 2 | Relapsed/ Refractory Multiple Myeloma | - | - |
AZD8848 | Phase 2 | Allergic Asthma | - | - |
Tiotropium 18 μg once-daily | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD9056 | Phase 2 | Rheumatoid Arthritis | - | - |
Casodex | Phase 2 | Gynaecomastia | - | - |
Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
AZD7594 DPI 55μg/50μg. | Phase 2 | Asthma | - | - |
AZD5423 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Iressa | Phase 2 | Locally Advanced Prostate Cancer | - | - |
AZD9164 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Bis-Choline Tetrathiomolybdate | Phase 2 | Wilson Disease | - | - |
Ticagrelor Tablets | Phase 2 | Coronary Artery Disease | - | - |
Formoterol Fumarate in the Pressair DPI, Low Dose | Phase 2 | Asthma | - | - |
Bertilimumab | Phase 2 | Pemphigoid, Bullous | - | - |
Sebelipase alfa 0.35 mg/kg | Phase 2 | Cholesterol Ester Storage Disease(CESD) | - | - |
KU-0059436 (AZD2281)(PARP inhibitor) | Phase 2 | Ovarian Neoplasm | - | - |
AZD2936 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
AZD5492 | Phase 2 | B-cell Malignancies | - | - |
Part A:AZD8233 | Phase 2 | Dyslipidemia | - | - |
AZD2281 | Phase 2 | Ovarian Neoplasms | - | - |
80/2.25 μg Symbicort pMDI | Phase 2 | Asthma | - | - |
AZD5851 | Phase 2 | Hepatocellular Carcinoma | - | - |
sibutramine | Phase 2 | Overweight | - | - |
Sodium Zirconium Cyclosilicate(ZS) | Phase 2 | Hyperkalemia | - | - |
Anastrozole and goserelin | Phase 2 | Breast Cancer | - | - |
AZD8931 | Phase 2 | Neoplasms | - | - |
Gefitinib, Cisplatin and Radiotherapy | Phase 2 | Cancer of Head and Neck | - | - |
AZD4017 | Phase 2 | Raised Intraocular Pressure | - | - |
AZD2423 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Ceralasertib | Phase 2 | Advanced Solid Tumours | - | - |
AZD4818 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Interferon beta-1a Nebuliser solution 48 μg/mL | Phase 2 | Asthma | - | - |
AC2993 2.5 mcg | Phase 2 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
AZD3480 | Phase 2 | ADHD | - | - |
Biological: AZD3152 | Phase 2 | COVID-19, SARS-CoV-2 | - | - |
VKA INR 2-3 | Phase 2 | Persistent or Permanent Nonvalvular Atrial Fibrillation | - | - |
AZD4360 | Phase 2 | Gastric Cancer | - | - |
FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) | Phase 2 | Metastatic Colorectal Cancer | - | - |
Selumetinib 75 mg | Phase 2 | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | - | - |
AZD4117 | Phase 2 | Influenza A | - | - |
Aclidinium bromide 100 μg bid | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AC2592 | Phase 2 | Congestive Heart Failure | - | - |
AZD7325 | Phase 2 | Anxiety Disorders | - | - |
AZD5462 | Phase 2 | Chronic Heart Failure | - | - |
CIN-107 | Phase 2 | Uncontrolled Hypertension | - | - |
AZD8630 | Phase 2 | Asthma | - | - |
AZD2389 | Phase 2 | Liver Fibrosis | - | - |
ER tablet 25 mg AZD3241 | Phase 2 | Parkinson's Disease | - | - |
Aclidinium/formoterol 400/12μg | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Gefitinib, radiotherapy | Phase 2 | Non-Metastatic Prostate Cancer | - | - |
Cotadutide 100 micrograms | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MEDI4736 monotherapy | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
AZD9773 (CytoFab) | Phase 2 | Severe Sepsis | - | - |
AZD8421 | Phase 2 | ER+ HER2- Advanced Breast Cancer | - | - |
Durvalumab and Tremelimumab | Phase 2 | Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma | - | - |
Cediranib 30 - 90 mg | Phase 2 | Cancer | - | - |
ACH-126,443 | Phase 2 | Hepatitis B, Chronic | - | - |
ALXN2350 | Phase 2 | BAG3 Mutation Associated Dilated Cardiomyopathy | - | - |
Aclidinium 200 μg / formoterol 12 μg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
ALXN2420 | Phase 2 | Acromegaly | - | - |
ALXN1210 | Phase 2 | PNH | - | - |
AZD3427 | Phase 2 | Pulmonary Hypertension (World Health Organization Group 2) | - | - |
Mitiperstat (AZD4831) | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD7798 | Phase 2 | Crohn's Disease | - | - |
AZD6765 | Phase 2 | Treatment Resistant Major Depressive Disorder | - | - |
Pramlintide and Metreleptin | Phase 2 | Obesity | - | - |
Omega-3 carboxylic acid | Phase 2 | Non-alcoholic Fatty Liver Disease (NAFLD | - | - |
terbutaline | Phase 2 | Exercise Induced Asthma | - | - |
Gefitinib and capecitabine | Phase 2 | Colorectal Cancer | - | - |
BMS-512148 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Monalizumab | Phase 2 | Non-small Cell Lung Cancer | - | - |
AZD1656 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Anastrozole (ARIMIDEX™) | Phase 2 | Gynecomastia | - | - |
AB248 | Phase 2 | Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
AZD2066 | Phase 2 | Reflux Episodes | - | - |
Fluorouracil (5-FU) | Phase 2 | Gastric Cancer | - | - |
Goserelin acetate | Phase 2 | Advanced Breast Cancer | - | - |
SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) | Phase 2 | AL Amyloidosis | - | - |
AZD3241 | Phase 2 | Multiple System Atrophy, MSA | - | - |
AS MDI 90 μg | Phase 2 | Asthma | - | - |
AZD2693 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
AZD8233 | Phase 2 | Hyperlipidaemia | - | - |
AZD3241 300 mg BID | Phase 2 | Parkinson's Disease | - | - |
AZD6750 | Phase 2 | Melanoma | - | - |
D9421-C, 9mg | Phase 2 | Crohn's Disease | - | - |
AS MDI | Phase 2 | Asthma | - | - |
Adavosertib | Phase 2 | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | - | - |
AZP-3601 | Phase 2 | Chronic Hypoparathyroidism | - | - |
AZD4901 (oral) | Phase 2 | Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder | - | - |
AZD 8529 | Phase 2 | Schizophrenia | - | - |
MEDI7352 | Phase 2 | Painful Osteoarthritis of the Knee | - | - |
AZD9567 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
AZD9668 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD6621 | Phase 2 | Prostate Cancer | - | - |
800 μg AZD7594 once daily | Phase 2 | Asthma | - | - |
AZD8601 | Phase 2 | Heart Failure | - | - |
5-flourouracil | Phase 2 | Squamous Cell Cancer | - | - |
MEDI-545 | Phase 2 | Systemic Lupus Erythematosus | - | - |
AZD4635 | Phase 2 | Prostate Cancer | - | - |
AZD6094 | Phase 2 | Papillary Renal Cell Cancer | - | - |
AZD0120 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
AZD3199 | Phase 2 | COPD | - | - |
AC2307 | Phase 2 | Obesity | - | - |
AZD5213 | Phase 2 | Mild Cognitive Impairment | - | - |
5-Fluorouracil (5-FU) | Phase 2 | Gastroesophageal Adenocarcinoma | - | - |
Administration of ceralasertib | Phase 2 | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | - | - |
Danvatirsen | Phase 2 | Non-Small Cell Lung Cancer | - | - |
AZD5718 | Phase 2 | Coronary Artery Disease | - | - |
MEDI2070 | Phase 2 | Crohn's Disease | - | - |
Verinurad 9 mg+Febuxostat 80 mg | Phase 2 | Hyperuricemia | - | - |
AZD3355 | Phase 2 | GERD | - | - |
ICI35,868 (propofol) | Phase 2 | Gastrointestinal Endoscopy | - | - |
exenatide (LY2148568) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
AZD4604 | Phase 2 | Asthma | - | - |
0.5% Roflumilast Cream | Phase 2 | Atopic Dermatitis | - | - |
AZD6244 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Verinurad | Phase 2 | Chronic Kidney Disease | - | - |
Ciclesonide/Formoterol Combination | Phase 2 | Asthma | - | - |
Olaparib Continuous (28-Day cycle) 300 mg BD. | Phase 2 | Metastatic Triple Negative Breast Cancer | - | - |
metreleptin | Phase 2 | Overweight | - | - |
RDEA3170 | Phase 2 | Gout and Hyperuricemia | - | - |
AZD9550 | Phase 2 | Overweight and Obesity | - | - |
AZD8871 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD2115 | Phase 2 | COPD | - | - |
Epanova (4 g) and Lovaza (4 g) | Phase 2 | Severe Hypertriglyceridemia | - | - |
AZD7009, no generic name available | Phase 2 | Atrial Fibrillation | - | - |
600 mg AZD7442 IV | Phase 2 | Coronavirus Disease 2019 (COVID-19) | - | - |
AZD5069 50mg | Phase 2 | Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD2327 | Phase 2 | Anxious Major Depressive Disorder | - | - |
Cerdulatinib | Phase 2 | Follicular Lymphoma (FL/Indolent NHL) | - | - |
AZD9977 | Phase 2 | Heart Failure | - | - |
ZD4054 10 mg | Phase 2 | Prostatic Neoplasms | - | - |
AZD0837 | Phase 2 | Nonvalvular Atrial Fibrillation | - | - |
ALXN1920 | Phase 2 | Primary Membranous Nephropathy | - | - |
AZD0901 | Phase 2 | Gastric Cancer | - | - |
CP-675,206 and leuprolide acetate and bicalutamide | Phase 2 | Prostatic Neoplasms | - | - |
AZD1446 | Phase 2 | Adult ADHD | - | - |
AZD0486 | Phase 2 | Chronic Lymphocytic Leukaemia | - | - |
AZD9150 | Phase 2 | Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck | - | - |
AZD0171 | Phase 2 | Locally Advanced or Metastatic Solid Tumours | - | - |
AZD8205 | Phase 2 | Breast Cancer | - | - |
Leucovorin LV | Phase 2 | Endometrial Cancer | - | - |
gefitinib and fulvestrant | Phase 2 | Breast Cancer | - | - |
Osimertinib + Savolitinib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Salmeterol | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Lamivudine | Phase 2 | HIV Infections | - | - |
AZD4512 | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
AZD1163 | Phase 2 | Rheumatoid Arthritis | - | - |
Neoadjuvant Olaparib monotherapy group | Phase 2 | Breast Cancer | - | - |
AZD0530 | Phase 2 | Breast Cancer | - | - |
AZD5305 | Phase 2 | Ovarian Cancer | - | - |
AZD7760 | Phase 2 | Staphylococcus Aureus | - | - |
AZD4573 | Phase 2 | Advanced Haematological Malignancies | - | - |
AZD2624 | Phase 2 | Schizophrenia | - | - |
Elvucitabine | Phase 2 | Human Immunodeficiency Virus (HIV)-1 Infection | - | - |
AZD9829 | Phase 2 | Hematological Malignancies | - | - |
AZD8871 100 µg | Phase 2 | Chronic Obstructive Pulmonary Disease COPD | - | - |
MEDI0382 low dose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ALXN2030 | Phase 2 | Antibody-Mediated Rejection | - | - |
AZD0754 | Phase 2 | Metastatic Prostate Cancer | - | - |
ALXN1840 | Phase 2 | Wilson Disease | - | - |
AZD5004 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
LAS100977 0.313 μg | Phase 2 | Asthma | - | - |
AZD5069 | Phase 2 | Asthma | - | - |
AZD8683, 50 mcg | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD9574 | Phase 2 | Advanced Solid Malignancies | - | - |
Formoterol fumarate (6 μg) | Phase 2 | Chronic Obstructive Pulmonary Disease - COPD | - | - |
Osimertinib 80 mg/40 mg | Phase 2 | Stage II-IIIB Non-small Cell Lung Carcinoma | - | - |
ZD1839 (IRESSA™) | Phase 2 | Head and Neck Cancer | - | - |
transthyretin-mediated amyloid cardiomyopathy
1 drug in this indication
transthyretin-mediated amyloidosis cardiomyopathy
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Beyond oncology
1 drug in this indication
Type 2 Diabetes Mellitus
1 drug in this indication
hypertension
1 drug in this indication
ATTR-CM
1 drug in this indication
first-line metastatic non-small cell lung cancer (mNSCLC)
1 drug in this indication
unresectable hepatocellular carcinoma
1 drug in this indication
Obesity/Overweight
1 drug in this indication
advanced breast cancer
1 drug in this indication
First-line ER-positive breast cancer
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
Breast Cancer
1 drug in this indication
Coronary Heart Disease (CHD)
1 drug in this indication
Urothelial Bladder Cancer
1 drug in this indication
Diabetes Mellitus, Type 2
1 drug in this indication
Mesothelioma
1 drug in this indication
Anticancer Treatment
1 drug in this indication
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AstraZeneca PLC's drug pipeline?→
CatalystAlert tracks 416 drug candidates in AstraZeneca PLC's (AZN) pipeline across Phase 3, Phase 2. Its lead program is Baxdrostat and dapagliflozin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AstraZeneca PLC's next FDA catalyst?→
AstraZeneca PLC's (AZN) next tracked catalyst is a Phase 2 expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AZN biotech catalysts?→
Add AZN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AstraZeneca PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.